phrykt

Cytokinetics Inc (CYTK): who owns it and who trades it

As of Nov 16, 2026, CYTK insiders reported 86 open-market sales worth $52M and no purchases in the last 12 months, with 91% of the sale value made under pre-set 10b5-1 plans. The largest seller was Robert I Blum (CEO), with $17.6M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Cytokinetics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and Congress mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns CYTK

478 funds and institutions reported CYTK shares worth $13.8B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 16.1%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

BlackRock, Inc.16.1%
T. Rowe Price Investment Management, Inc.15.0%
Wellington Management Group LLP5.6%
Vanguard Portfolio Management LLC5.4%
State Street Corp5.2%
Vanguard Capital Management LLC4.9%
FMR LLC (Fidelity)4.0%
Avoro Capital Advisors LLC4.0%
Bank of America Corp3.7%
Geode Capital Management, LLC3.0%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.20.09M16.15%$1.7B+21%
T. Rowe Price Investment Management, Inc.18.72M15.04%$1.6B+7%
Wellington Management Group LLP6.93M5.57%$591M-13%
Vanguard Portfolio Management LLC6.71M5.39%$572M+15%
State Street Corp6.49M5.22%$553M+13%
Vanguard Capital Management LLC6.12M4.92%$521M+11%
FMR LLC (Fidelity)5.03M4.04%$429M-53%
Avoro Capital Advisors LLC5.00M4.02%$426M+50%
Bank of America Corp4.64M3.73%$395M+48%
Geode Capital Management, LLC3.71M2.98%$316M+15%
Rtw Investments, LP2.86M2.30%$244M+5%
Polar Capital Holdings Plc2.25M1.81%$192M+36%
T. Rowe Price Associates1.96M1.57%$167M+24%
Goldman Sachs Group Inc1.76M1.42%$150M-20%
Capital Research Global Investors1.69M1.36%$144M+119%
Northern Trust Corp1.65M1.32%$140M+14%
William Blair Investment Management, LLC1.60M1.29%$137M+47%
Integral Health Asset Management, LLC1.60M1.29%$136MNo change
JPMorgan Chase & Co1.59M1.28%$139M–
Point72 Asset Management, L.P.1.59M1.28%$135M+154%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, CYTK insiders reported $0 of open-market purchases and $52M of sales. 91% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$52M
86 trades, 10 people
Sales under a 10b5-1 plan
91%
Share of sale value
Latest trade
Nov 9, 2026
Filed Nov 12, 2026

Purchases and sales by month

$8.8M$8.8MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 9, 2026B Lynne ParshallDirectorSale plan2,445$54.17$132KForm 4
Nov 9, 2026B Lynne ParshallDirectorSale plan2,555$55.26$141KForm 4
Nov 3, 2026Fady Ibraham MalikVice presidentSale plan3,500$62.93$220KForm 4
Nov 2, 2026Robert I BlumCEOSale plan7,500$62.81$471KForm 4
Oct 20, 2026Fady Ibraham MalikVice presidentSale plan3,500$64.01$224KForm 4
Oct 12, 2026Robert I BlumCEOSale plan7,500$62.88$472KForm 4
Oct 6, 2026Fady Ibraham MalikVice presidentSale plan3,500$61.38$215KForm 4
Sep 28, 2026Robert I BlumCEOSale plan7,500$65.46$491KForm 4
Sep 22, 2026Fady Ibraham MalikVice presidentSale plan3,500$68.29$239KForm 4
Sep 15, 2026Robert E LandryDirectorSale plan1,000$72.13$72.1KForm 4
Sep 15, 2026Robert I BlumCEOSale plan97,926$69.33$6.8MForm 4
Sep 14, 2026Robert I BlumCEOSale plan7,500$73.44$551KForm 4
Sep 11, 2026Robert E LandryDirectorSale plan1,000$74.66$74.7KForm 4
Sep 8, 2026Fady Ibraham MalikVice presidentSale plan3,500$75.46$264KForm 4
Sep 1, 2026B Lynne ParshallDirectorSale plan5,000$71.48$357KForm 4
Aug 31, 2026Andrew CallosVice presidentSale plan10,000$70.24$702KForm 4
Aug 31, 2026Robert I BlumCEOSale plan7,500$70.24$527KForm 4
Aug 18, 2026Fady Ibraham MalikVice presidentSale plan3,500$75.82$265KForm 4
Aug 10, 2026Robert I BlumCEOSale plan7,500$76.76$576KForm 4
Jul 30, 2026Andrew CallosVice presidentSale plan14,000$79.88$1.1MForm 4
Jul 27, 2026Robert I BlumCEOSale plan7,500$80.87$607KForm 4
Jul 21, 2026Fady Ibraham MalikVice presidentSale plan3,500$80.59$282KForm 4
Jul 13, 2026Robert I BlumCEOSale plan10$82.02$820Form 4
Jul 13, 2026Robert I BlumCEOSale plan7,490$82.02$614KForm 4
Jul 7, 2026Fady Ibraham MalikVice presidentSale plan3,500$86.62$303KForm 4
Jul 1, 2026Robert I BlumCEOSale plan7,500$84.92$637KForm 4
Jul 1, 2026Andrew CallosVice presidentSale plan15,000$85.80$1.3MForm 4
Jul 1, 2026Sung LeeCFOSale plan1,112$87.79$97.6KForm 4
Jun 29, 2026Sung LeeCFOSale plan3,134$85.00$266KForm 4
Jun 24, 2026Sung LeeCFOSale plan38,730$82.30$3.2MForm 4
Jun 23, 2026Fady Ibraham MalikVice presidentSale plan3,500$79.51$278KForm 4
Jun 15, 2026Robert I BlumCEOSale plan7,500$70.46$528KForm 4
Jun 9, 2026Fady Ibraham MalikVice presidentSale plan3,500$67.98$238KForm 4
Jun 1, 2026Edward M. MD KayeDirectorSale plan2,933$76.09$223KForm 4
Jun 1, 2026Andrew CallosVice presidentSale plan15,000$74.08$1.1MForm 4
Jun 1, 2026B Lynne ParshallDirectorSale plan5,000$74.08$370KForm 4
May 27, 2026Robert I BlumCEOSale plan7,500$77.21$579KForm 4
May 19, 2026Fady Ibraham MalikVice presidentSale plan3,500$75.69$265KForm 4
May 14, 2026Robert I BlumCEOSale plan7,500$77.92$584KForm 4
May 5, 2026Fady Ibraham MalikVice presidentSale plan3,500$77.37$271KForm 4
May 5, 2026Wendell WierengaDirectorSale plan4,032$75.00$302KForm 4
May 5, 2026Sung LeeCFOSale plan23,906$76.87$1.8MForm 4
May 5, 2026John T HendersonDirectorSale plan20,000$75.97$1.5MForm 4
May 5, 2026Andrew CallosVice presidentSale plan11,333$77.25$875KForm 4
May 1, 2026Andrew CallosVice presidentSale plan15,857$65.00$1MForm 4
Apr 30, 2026Andrew CallosVice presidentSale plan15,000$63.26$949KForm 4
Apr 29, 2026Robert I BlumCEOSale plan7,500$59.62$447KForm 4
Apr 21, 2026Fady Ibraham MalikVice presidentSale plan3,500$65.69$230KForm 4
Apr 15, 2026Andrew CallosVice presidentSale plan7,449$66.02$492KForm 4
Apr 15, 2026Robert I BlumCEOSale plan7,500$65.38$490KForm 4
Apr 7, 2026Fady Ibraham MalikVice presidentSale plan1,000$64.75$64.8KForm 4
Apr 7, 2026Fady Ibraham MalikVice presidentSale plan3,500$65.21$228KForm 4
Apr 1, 2026Robert I BlumCEOSale plan7,500$66.63$500KForm 4
Mar 31, 2026Andrew CallosVice presidentSale plan3,639$65.00$237KForm 4
Mar 18, 2026Andrew CallosVice presidentSale plan1,930$62.07$120KForm 4
Mar 17, 2026Sung LeeCFOSale4,935$62.15$307KForm 4
Mar 17, 2026Andrew CallosVice presidentSale5,626$62.15$350KForm 4
Mar 17, 2026Andrew CallosVice presidentSale2,916$62.15$181KForm 4
Mar 17, 2026Fady Ibraham MalikVice presidentSale4,397$62.15$273KForm 4
Mar 17, 2026Fady Ibraham MalikVice presidentSale7,636$62.15$475KForm 4
Mar 17, 2026Robert I BlumCEOSale12,673$62.15$788KForm 4
Mar 17, 2026Robert I BlumCEOSale23,928$62.15$1.5MForm 4
Mar 16, 2026Andrew CallosVice presidentSale plan1,709$61.03$104KForm 4
Mar 9, 2026Andrew CallosVice presidentSale2,582$60.72$157KForm 4
Mar 9, 2026Fady Ibraham MalikVice presidentSale2,907$60.72$177KForm 4
Mar 9, 2026Robert I BlumCEOSale7,931$60.72$482KForm 4
Mar 5, 2026Andrew CallosVice presidentSale plan11,000$61.88$681KForm 4
Mar 5, 2026Andrew CallosVice presidentSale plan15,000$61.87$928KForm 4
Mar 2, 2026B Lynne ParshallDirectorSale plan5,000$61.21$306KForm 4
Mar 2, 2026Andrew CallosVice presidentSale plan886$61.62$54.6KForm 4
Feb 5, 2026Andrew CallosVice presidentSale plan15,000$61.93$929KForm 4
Feb 2, 2026Andrew CallosVice presidentSale plan886$62.10$55KForm 4
Jan 5, 2026Andrew CallosVice presidentSale plan15,000$60.28$904KForm 4
Jan 2, 2026Andrew CallosVice presidentSale plan913$62.09$56.7KForm 4
Jan 2, 2026Andrew CallosVice presidentSale plan885$63.16$55.9KForm 4
Dec 29, 2025Andrew CallosVice presidentSale plan1,809$62.44$113KForm 4
Dec 22, 2025Wendell WierengaDirectorSale plan20,000$66.14$1.3MForm 4
Dec 16, 2025Fady Ibraham MalikVice presidentSale plan2,200$61.24$135KForm 4
Dec 8, 2025Andrew CallosVice presidentSale plan1,042$65.96$68.7KForm 4
Dec 5, 2025Andrew CallosVice presidentSale plan52,486$65.95$3.5MForm 4
Dec 2, 2025John T HendersonDirectorSale plan8,750$63.90$559KForm 4
Dec 2, 2025Fady Ibraham MalikVice presidentSale plan2,200$63.89$141KForm 4
Dec 1, 2025Edward M. MD KayeDirectorSale plan28,064$66.72$1.9MForm 4
Dec 1, 2025Robert Arthur HarringtonDirectorSale plan2,150$66.80$144KForm 4
Nov 19, 2025B Lynne ParshallDirectorSale plan5,000$64.73$324KForm 4
Nov 18, 2025Fady Ibraham MalikVice presidentSale plan2,200$66.45$146KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Robert I BlumPresident & CEO, Director–$17.6MNov 2, 2026
Andrew CallosEVP, Chief Commercial Officer–$16MAug 31, 2026
Sung LeeEVP, Chief Financial Officer–$5.7MJul 1, 2026
Fady Ibraham MalikEVP Research & Development–$4.9MNov 3, 2026
Edward M. MD KayeDirector–$2.1MJun 1, 2026
John T HendersonDirector–$2.1MMay 5, 2026
B Lynne ParshallDirector–$1.6MNov 9, 2026
Wendell WierengaDirector–$1.6MMay 5, 2026
Robert E LandryDirector–$147KSep 15, 2026
Robert Arthur HarringtonDirector–$144KDec 1, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CYTK short interest

High short interest. 12.9% of CYTK shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 9%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 17.93M CYTK shares were sold short, 12.9% of the shares outstanding, down 3.7% from the report before. At the average daily volume of 1.27M shares, buying them all back would take about 14.2 trading days (days to cover).

Shares short, % of all shares

12.9%May 15Oct 3014.5%

Days to cover

14.2May 15Oct 3015.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202617.93M12.90%-4%1.27M14.2
Oct 15, 202618.63M13.40%-4%2.14M8.7
Sep 30, 202619.33M13.91%+11%2.31M8.4
Sep 15, 202617.48M12.57%+0%1.66M10.6
Aug 31, 202617.44M12.55%+7%1.79M9.7
Aug 14, 202616.32M11.74%+7%2.12M7.7
Jul 31, 202615.30M12.30%-10%1.59M9.6
Jul 15, 202617.05M13.70%-3%1.90M9.0
Jun 30, 202617.57M14.12%+19%3.34M5.3
Jun 15, 202614.77M11.87%-5%1.59M9.3
May 29, 202615.50M12.46%-6%1.81M8.6
May 15, 202616.46M13.23%+4%4.86M3.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded CYTK

Since Nov 17, 2024, 2 members of Congress reported 4 purchases and 1 sale of CYTK. The latest was a purchase by Gilbert Ray Cisneros, Jr. on Sep 29, 2026, reported Oct 12, 2026.

Purchases 4Sales 1

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
Sep 29, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfOct 12, 2026Report
Jun 30, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfJul 2, 2026Report
Oct 9, 2025Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfNov 18, 2025Report
Jun 17, 2025Lisa C. McClain (R-MI)Sale$1K–$15KSpouseAug 13, 2025Report
Jun 11, 2025Lisa C. McClain (R-MI)Purchase$1K–$15KSpouseAug 13, 2025Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

Cytokinetics company events

Cytokinetics filed 12 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 4, 2026.

  1. Nov 4, 2026ResultsReleased financial results. Filing
  2. Aug 28, 2026AnnouncementCytokinetics, Incorporated issued a press release announcing its presentation of the full results of ACACIA-HCM at the European Society of Cardiology (ESC) Congress 2026 and published in the New England Journal of Medicine. Filing
  3. Aug 13, 2026AnnouncementCytokinetics, Incorporated filed a complaint in the United States District Court for the District of Delaware against Bristol-Myers Squibb Company and MyoKardia, Inc. The complaint seeks a declaratory judgment that the Company does not infringe U.S. Patent No. 12,616,697 and that the claims of the… Filing
  4. Aug 6, 2026ResultsReleased financial results. Filing
  5. May 27, 2026VoteReported shareholder vote results. Filing
  6. May 8, 2026AnnouncementCytokinetics, Incorporated entered into an underwriting agreement with Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Jefferies LLC, as representatives of the several underwriters named therein, relating to the public offering, issuance and sale of 9,859,155… Filing
  7. May 5, 2026AnnouncementCytokinetics, Incorporated released its current corporate presentation, which is attached hereto as Exhibit 99.1 and is incorporated by reference in this Item 8.01. Filing
  8. May 5, 2026ResultsReleased financial results. Filing
  9. Feb 24, 2026ResultsReleased financial results. Filing
  10. Feb 17, 2026AnnouncementCytokinetics, Incorporated today announced that the European Commission has approved MYQORZO® (aficamten), 5 mg, 10 mg, 15 mg and 20 mg tablets for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy in adult patients. Filing
  11. Dec 19, 2025AnnouncementCytokinetics, Incorporated announced that the U.S. Food and Drug Administration has approved MYQORZO™ (aficamten), 5 mg, 10 mg, 15 mg, 20 mg tablets, for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms. Filing
  12. Dec 12, 2025AnnouncementCytokinetics, Incorporated announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending marketing authorization in the European Union for MYQORZO® (aficamten), a cardiac myosin inhibitor, for the treatment of… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Cytokinetics financials

Famous investors that hold CYTK

4 of the 50 well-known investors we track reported holding CYTK in their latest 13F filing. The largest position is Ken Fisher's, worth $54M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Fisher · Fisher Asset ManagementQ3 2026818,832$54M0.0%+10%
Israel Englander · Millennium ManagementQ3 2026277,135$18.3M0.0%+153%
Ken Griffin · Citadel AdvisorsQ3 2026204,231$13.5M0.0%-68%
Paul Tudor Jones · Tudor Investment CorpQ3 20269,770$644K0.0%-89%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named CYTK in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Wellington Management Group LLP13G/A7.7%
Nov 16, 2026Wellington Management Group LLP13G/A7.7%
Nov 10, 2026STATE STREET CORPORATION13G5.1%
Nov 10, 2026STATE STREET CORPORATION13G5.1%

Questions about Cytokinetics Inc (CYTK) stock

Who owns the most CYTK stock?

The largest reported owner of Cytokinetics Inc (CYTK) is BlackRock, Inc., with 16.1% of the company. In total, 478 funds and institutions reported holding CYTK at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are CYTK insiders buying or selling?

In the last 12 months, CYTK insiders reported no open-market purchases and 86 sales worth $52M. The latest trade was on Nov 9, 2026. See every trade.

What is the short interest in CYTK?

As of Oct 30, 2026, 17.93M CYTK shares were sold short, 12.9% of the shares outstanding, down 3.7% from the report before. At the average daily volume of 1.27M shares, buying them all back would take about 14.2 trading days (days to cover). See the history.

Have members of Congress traded CYTK?

Yes. 2 members of Congress reported 4 purchases and 1 sale of CYTK since Nov 17, 2024. The latest was reported on Oct 12, 2026. See the trades.

Which famous investors hold CYTK?

4 of the 50 well-known investors we track reported CYTK in their latest 13F filing, including Ken Fisher, Israel Englander, Ken Griffin. The largest position is worth $54M. See all holders.

Executive pay

Cytokinetics's chief executive was paid a total of $11.9M for the year ended Dec 31, 2025, down 17% from $14.4M the year before. In the last 12 months, Cytokinetics's executives and directors bought no stock on the open market and sold $52M.

Chief executive, total pay$11.9MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$15.8MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$4.5MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.